In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
OBJECTIVE
To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.


RESULTS
The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC(90) values of 0.125 mg/L. Linezolid was active against all isolates with MIC(50) and MIC(90) values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.


CONCLUSIONS
Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.
Guna
Remedios
R
Departamento de Microbiología, Facultad de Medicina y Hospital Clínico Universitario, Universidad de Valencia, Av. Blasco Ibáñez 17, 46010 Valencia, Spain.
Muñoz
Carlos
C
Domínguez
Victoria
V
García-García
Angeles
A
Gálvez
Jorge
J
de Julián-Ortiz
Jesús-Vicente
JV
Borrás
Rafael
R
D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D019909:Mycobacterium kansasii / Q000187:drug effects*; D023303:Oxazolidinones / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011804:Quinolines; D017291:Clarithromycin; D000069349:Linezolid; D000077266:Moxifloxacin